EasyM Technology.

Key Highlights.

Results Highlights.

More sensitive than SPEP1
More sensitive than IFE1

How EasyM™ Works.

EasyM™ is a high sensitivity, truly personalized, non-invasive mass spectrometry-based assay for the routine monitoring of M-protein in the peripheral blood of patients with Multiple Myeloma (MM).

Unlike other high sensitivity minimal residual disease (MRD) tests, EasyM™ does not require bone marrow samples, allowing for flexible, non-invasive sampling as frequently as needed.

Rapid Novor’s proven de novo protein sequencing technology enables us to sequence the patient’s unique M-protein signature directly from an initial blood sample.  Using this unique sequence, EasyM™ measures the amount of M-protein for the precise and reliable monitoring of MRD status below the detection limits of conventional blood tests.

Sample Requirements.

  • Preferred: Serum (gold top collection tube with gel)
  • Acceptable: red top collection tube Gel/No Gel
  • Minimum Volume: 2 mL


EasyM has been approved as a Laboratory Developed Test (LDT) by CLIA/COLA in all US states except CA, NY, RI, and PA. We are seeking further certification in the remaining states, by the US FDA and by Health Canada.

1. Liyasova M, et al. Clin Cancer Res. 2021; 27(18):5028-5037